A Study to Observe Characteristics of Rheumatoid Arthritis in Patients Using Infliximab (Study P04250) (REMARK)

Merck Sharp & Dohme (MSD)

Status: Completed

Conditions: Rheumatoid Arthritis

Treatments: Biological: Infliximab

Study type: Observational

Funder types: Industry

Identifiers

NCT00705289

P04250

Details and patient eligibility

About

This 14-week non-interventional study will observe patients with rheumatoid arthritis (RA) who are being treated with infliximab for the first time, in order to learn about their disease characteristics. Patients in this study will be treated for RA with infliximab and in a usual manner as decided by their physician.

Enrollment: 728 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Subject has been diagnosed with RA
• Physician has decided, with the subject's consent, to begin treatment with infliximab
• Written informed consent form signed by both the subject and the physician.

Exclusion criteria

• Subjects who have previously been exposed to infliximab

Trial design

728 participants in 1 patient group

RA Subjects/ Infliximab 3 mg/kg

Description:

Subjects with rheumatoid arthritis (RA) in whom treatment with infliximab is started for the first time, in line with current clinical practice (and thus consistent with the European Summary of Product Characteristics \[SPC\] of Remicade®).

Treatment:

Biological: Infliximab